Increased expressions of GLUT1 and GLUT3 are also linked with worse clinical outcomes in patients with glioblastoma and colorectal carcinoma (Cosset et al., 2017, Dai et al., 2020). This evidence concerns the gene SLC2A3 and colorectal carcinoma.